- Lp(a) is a genetically determined lipoprotein that adds real cardiovascular risk on top of LDL and ApoB.
- It barely responds to diet, exercise or standard statins, which is why it is missing from most routine panels and why most people with high Lp(a) do not know they have it.
- You usually only need one accurate baseline measurement in your life, because the level stays roughly stable over decades.
- Inside our membership the test is part of the quarterly Biomarker Audit at no extra charge and the $299 monthly fee covers the clinician who reads it.
Most people with a dangerous Lp(a) level have never heard of the marker, let alone learned what a high result means. Their annual physical reported total cholesterol, LDL, HDL and triglycerides. Lp(a) was never on the menu. Meanwhile, the level was quietly set at birth, unaffected by everything they had been doing right.
We include Lp(a) in every intake Biomarker Audit for exactly this reason. It is the single most common inherited risk marker we find that standard care never looked for.
What Lp(a) actually is
Lp(a), pronounced L-P-little-a, is an LDL-like particle carrying an extra protein called apoprotein(a). That extra protein makes the particle stickier and more prone to embedding in artery walls. Higher levels mean more of this particle circulating for a lifetime.
The level is set almost entirely by genetics. Diet, exercise and statins move it very little. Family history tells part of the story, but the only way to know your number is to measure it.
Why one draw is usually enough
Most lab values swing with the season. Lp(a) does not. It stays within a narrow band for most of a lifetime, which is the unusual property that makes a single accurate baseline so useful.
We draw it once at intake and we keep it on the audit panel anyway, partly to confirm stability and partly because the clinical team reads the whole panel together. If it ever moves meaningfully, something unusual is going on and that itself is a finding worth investigating.
What a high result actually means
| Lp(a) level | Typical interpretation | What it usually triggers |
|---|---|---|
| Under 30 mg/dL (or under 75 nmol/L) | Lower genetic risk from this marker | No special action |
| 30 to 50 mg/dL | Moderately elevated | More aggressive ApoB and LDL management |
| Above 50 mg/dL (above about 125 nmol/L) | Elevated, guideline-recognized risk factor | Tighter particle count targets, earlier statin conversations, family screening |
Interpretation varies by lab and by unit, which is part of why a clinician reading the full panel matters more than a reference range on a printout. A high Lp(a) is not a diagnosis. It is a modifier of how aggressively we treat everything else.
What treatment actually looks like
Here is the honest part. Very few medicines lower Lp(a) meaningfully today. PCSK9 inhibitors reduce it modestly. Newer agents specifically targeting Lp(a) are in late-stage trials and are not yet standard of care. Statins lower LDL and ApoB but barely touch Lp(a).
So what do we do when it is high? We treat the particles we can move harder. That means tighter ApoB targets, earlier conversations about lipid-lowering therapy, closer attention to hs-CRP and blood pressure and sometimes earlier coronary calcium imaging depending on the overall picture. A high Lp(a) is a reason to be more aggressive with everything else and that aggression is a clinical judgment our physicians make inside the membership rather than a separate visit.
The family conversation
Because Lp(a) is inherited, one high result usually means siblings, children and sometimes parents should be tested too. Patients often find this the most meaningful part of the finding. It is one lab draw that changes the screening path for an entire family.
We help patients frame that conversation for relatives. It is not a scary conversation. It is information that arrived decades before symptoms, which is the most useful timing there is.
A worked example, anonymized
A patient in her early fifties came to us with a decade of clean standard panels and a father who had a bypass at fifty-eight. Her LDL cholesterol was 104, technically fine. Her Lp(a), never before measured, came back at 91 mg/dL.
That single result reframed her whole risk picture. Her ApoB target tightened, a statin conversation that had never felt urgent became immediate and her two adult children were tested. One of them carried the same level.
The pattern repeats often enough that we consider the Lp(a) draw among the highest-yield tests on the entire panel. It is also the one most likely to be missing from a decade of annual physicals, because nobody ordered it and nobody was paid to look for it.
Why standard physicals miss it
The standard lipid panel answers the question most guidelines were built around, which is whether LDL cholesterol is elevated. Lp(a) requires a separate test that many insurance plans cover only when specific risk criteria are met. Cash-pay patients often discover they can order it easily and cheaply on their own.
Inside our membership there is no prior authorization conversation. The Biomarker Audit includes it from intake onward and the result is read by the same clinician who manages your ApoB, your thyroid and everything else on the panel.
What a high Lp(a) changes for a GLP-1 patient
Patients on medical weight loss therapy sometimes assume the GLP-1 will fix everything the panel shows. Lp(a) is the exception that teaches the rule. Weight loss improves insulin resistance, liver fat, blood pressure and often ApoB. It does nothing to Lp(a), because the level is genetic.
That is exactly why the marker belongs on the panel rather than in a separate cardiology silo. A patient whose Lp(a) is high and whose ApoB falls with weight loss is a patient whose remaining risk has become clearer and whose lipid therapy decisions should be made against that updated picture rather than against hope.
Who this matters most for
If you have a family history of early heart attack or stroke, an Lp(a) baseline is the single most informative test you have probably never had. If you have already had a high ApoB or LDL on a standard panel, Lp(a) tells you how much of that risk is genetic traffic rather than lifestyle drift. If you are the kind of patient who wants the full picture rather than the routine one, this is the test you were looking for and did not know the name of.
Frequently asked questions
What is a normal Lp(a) level?
Most labs consider under 30 mg/dL or under about 75 nmol/L, within the lower-risk range. Levels above 50 mg/dL or about 125 nmol/L, are treated as an elevated risk marker worth acting on. Units vary between labs, which is one more reason a clinician should read the result in context.
Can diet or exercise lower Lp(a)?
Barely. Lp(a) is genetically determined and stays within a narrow band for life regardless of lifestyle. It is one of the few numbers on a panel that lifestyle does not move.
How often should Lp(a) be retested?
Once accurately establishes your baseline, because the level is genetically stable. We keep it on the quarterly panel anyway so the full lipid picture is always read together.
Does insurance cover the Lp(a) test?
Sometimes, depending on the plan and the risk criteria. Cash-pay pricing through a lab network is usually modest and inside our membership the test is part of the quarterly Biomarker Audit rather than a separate bill.
If my Lp(a) is high, will statins help?
Statins lower LDL and ApoB substantially and Lp(a) barely at all. A high Lp(a) is a reason to treat the particles you can move more aggressively and that is exactly how our protocols use the finding.
Should my family members get tested?
Yes. Lp(a) is inherited, so a high result means siblings, children and sometimes parents should have a baseline drawn. One test often changes the screening path for an entire family.
Is Lp(a) the same thing as ApoB?
No. ApoB is the protein carried by every atherogenic particle, including the Lp(a) particle. Lp(a) is a specific particle type with its own extra protein. The two tests answer different questions and are read together.
What treatments are coming for high Lp(a)?
Medicines specifically designed to lower Lp(a) are in late-stage clinical trials. They are not yet standard of care and our protocols follow the evidence as it develops rather than promising results ahead of it.
Related guides
- ApoB went up on a GLP-1: why it happens and the labs that fix it
- hs-CRP blood test: what high inflammation means
- Cardiometabolic optimization: the definitive guide
- Direct primary care
Sources
- Lp(a): structure, genetics and atherogenicity, PubMed review
- CDC, cholesterol and lipid reference information
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/